Clinical trial Recruiting at 1 site Observational Ages 18 and up Men only

Impact of 177Lu-PSMA therapy on kidney function in prostate cancer patients

Official title: 177Lu-PSMA-KiRi-trial

Run by Technical University of Munich · NCT06720532 · Data updated 2026-11-12

This study is testing how a new prostate cancer treatment affects kidney function in men with advanced prostate cancer over five years.

More Kidney Disease trials

Quick facts

Study typeObservational
Ages18 Years and up
SexMen only
Enrollment100 (estimated)
SponsorTechnical University of Munich
Academic / other
Locations1 site (Munich)
StatusRecruiting
StartedAugust 5, 2024
Main results expectedAugust 1, 2027
Study endsAugust 1, 2031
Registry record updatedDecember 6, 2024
Trial IDNCT06720532 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults over 18 years with metastatic castration-resistant prostate cancer who are starting their first cycle of 177Lu-PSMA therapy.

Probably not a fit

Patients who are not starting 177Lu-PSMA therapy or are under 18 years old will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess how 177Lutetium-Prostate Specific Membrane Antigen (PSMA) Radioligand Therapy affects kidney function in patients with metastatic castration-resistant prostate cancer (mCRPC). It will monitor kidney function using routine markers like creatinine and cystatin C before, during, and after therapy, with follow-ups extending up to 5 years. The study will also collect additional biomarkers and patient-reported outcomes to identify risk factors for chronic kidney disease and correlate them with clinical data. A total of 100 patients will be included to ensure robust data collection and analysis.

Why it matters

Potential benefit: If successful, this study could help identify kidney function decline in prostate cancer patients undergoing treatment, leading to better management of kidney health.

How similar studies have gone: While there have been studies on kidney function in cancer therapies, this specific approach focusing on 177Lu-PSMA therapy and its renal impact is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with mCRPC starting 177Lu-PSMA RLT at the Klinikum rechts der Isar at the time of therapy initiation (1st cycle).

Exclusion Criteria:

* Missing or incomplete informed consent.
* age below 18 years

Where it's running

  • Klinikum rechts der Isar, München, Bavaria 81675
    Munich, Germany
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.